Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Thyroid Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Contact: Study coordinator (Paul Swiecicki, M.D.) · pswiecic@med.umich.edu
Contact: Study coordinator (Francis Worden, M.D.) · fworden@umich.edu · 734-936-0453
Contact: Principal Investigator (Paul Swieciki, M.D.)

Study leads

Paul Swiecicki, M.D.
Principal Investigator
University of Michigan Rogel Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Metastatic Malignant Solid Neoplasm · Metastatic Melanoma · Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Abroad (travel likely)RecruitingPHASE1

Duarte, United States · Los Angeles, United States

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Bethesda, United States

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Non-small Cell Lung Cancer · Histiocytic Neoplasm · Histiocytosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gilbert, United States · Los Angeles, United States

MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC

Thyroid Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China